Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
27.73
-0.33 (-1.18%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Bicara Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Bicara Therapeutics stock has a consensus rating of "Buy" and an average price target of $31.46. The average 1-year stock price forecast is 13.45% higher than the current stock price, while the lowest is $16 (-42.30%) and the highest is $46 (+65.89%).
Price Target: $31.46 (+13.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 9 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $28 | Buy | Maintains | $28 | +0.97% | Jul 28, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 2, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -35.09% | Jun 2, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $25 → $16 | Hold | Reiterates | $25 → $16 | -42.30% | Jun 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $42 | Buy | Reiterates | $42 | +51.46% | Jun 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.48
from -2.52
EPS Next Year
-3.63
from -3.48
EPS and Forward PE are based on non-GAAP adjusted numbers.